FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379338421> ?p ?o ?g. }

• W4379338421 endingPage "8582" @default.
• W4379338421 startingPage "8582" @default.
• W4379338421 abstract "8582 Background: Tarlatamab, a BiTE molecule targeting DLL3 and CD3, is being studied in patients (pts) with extensive stage small cell lung cancer (ES-SCLC). 1 Up to 25% of pts diagnosed with SCLC have brain metastases (BM) and 50% or more will develop BM during the course of the disease. Pts with ES-SCLC and BM have poor prognosis and quality of life. We analyzed the characteristics and outcomes of pts included in the tarlatamab phase 1 study (NCT03319940) who had baseline BM vs those who did not. Methods: Pts included in the phase 1 trial had SCLC that progressed after ≥1 platinum-based regimen and received tarlatamab (0.003–100 mg IV). Pts with treated BM were eligible if local therapy was delivered ≥ 2 weeks prior to first tarlatamab dose. Results: As of 03 January 2023, 192 pts had received tarlatamab as monotherapy. Median age was 62 (range, 32–80) y; 188 pts (98%) had ECOG PS 0–1 and median prior therapy lines was 2 (range, 1–6), with 107 pts (56%) receiving prior anti-PD1/PD-L1. 48 pts (25%) had BM at screening and 142 (74%) did not (No BM); data was missing for 2 pts (1%). Pts with BM were more likely to have received > 3 prior lines of therapy (BM, 29%; No BM, 9%) and have a record of prior brain radiation (BM, 85%; No BM, 40%); otherwise, characteristics of pts with BM were generally similar to those without. Tarlatamab delivered comparable activity in pts with BM vs. those without in terms of objective response rate (ORR; 20%, 25%) and disease control rate (DCR; 59%, 50%) (Table). Median duration of response (DoR) was 14.9 months (BM) vs. 13.0 months (no BM). Median overall survival (OS) was 13.2 months in the BM group vs 15.5 months in the no BM group. Safety outcomes were similar in terms of treatment-related AEs (TRAEs; BM, 90%; No BM, 94%) and grade (gr) ≥ 3 (BM, 38%; No BM, 39%). Groups were also comparable with respect to immune effector cell-associated neurotoxicity syndrome (ICANS) and associated neurologic events (any-grade, 6% vs 9%; gr ≥ 3, 4% vs 4%) and neutropenia (any-grade, 10% vs 15%; gr ≥ 3, 8% vs 8%). AEs numerically different in the BM vs No BM group included gr ≥ 4 TRAEs (17%, 7%) and any-grade CRS (67%, 54%). The only grade 5 TRAE (pneumonitis) occurred in the BM group. Conclusions: Tarlatamab continues to show promising efficacy and is generally safe in pts with ES SCLC irrespective of the presence of BM. Rates of ICANS and associated neurologic AEs were comparable between those with and without BM at baseline. Reference: 1. Paz-Ares L, et al. J Clin Oncol. DOI:10.1200/JCO.22.02823. Clinical trial information: NCT03319940 . [Table: see text]" @default.
• W4379338421 created "2023-06-05" @default.
• W4379338421 creator A5003842671 @default.
• W4379338421 creator A5005405732 @default.
• W4379338421 creator A5008171524 @default.
• W4379338421 creator A5012061864 @default.
• W4379338421 creator A5015060656 @default.
• W4379338421 creator A5028146377 @default.
• W4379338421 creator A5046900095 @default.
• W4379338421 creator A5049294543 @default.
• W4379338421 creator A5051744290 @default.
• W4379338421 creator A5052765751 @default.
• W4379338421 creator A5057085664 @default.
• W4379338421 creator A5060793722 @default.
• W4379338421 creator A5068824818 @default.
• W4379338421 creator A5075792907 @default.
• W4379338421 creator A5076085296 @default.
• W4379338421 creator A5077287358 @default.
• W4379338421 creator A5088647389 @default.
• W4379338421 creator A5090262803 @default.
• W4379338421 date "2023-06-01" @default.
• W4379338421 modified "2023-10-18" @default.
• W4379338421 title "Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis." @default.
• W4379338421 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.8582" @default.
• W4379338421 hasPublicationYear "2023" @default.
• W4379338421 type Work @default.
• W4379338421 citedByCount "0" @default.
• W4379338421 crossrefType "journal-article" @default.
• W4379338421 hasAuthorship W4379338421A5003842671 @default.
• W4379338421 hasAuthorship W4379338421A5005405732 @default.
• W4379338421 hasAuthorship W4379338421A5008171524 @default.
• W4379338421 hasAuthorship W4379338421A5012061864 @default.
• W4379338421 hasAuthorship W4379338421A5015060656 @default.
• W4379338421 hasAuthorship W4379338421A5028146377 @default.
• W4379338421 hasAuthorship W4379338421A5046900095 @default.
• W4379338421 hasAuthorship W4379338421A5049294543 @default.
• W4379338421 hasAuthorship W4379338421A5051744290 @default.
• W4379338421 hasAuthorship W4379338421A5052765751 @default.
• W4379338421 hasAuthorship W4379338421A5057085664 @default.
• W4379338421 hasAuthorship W4379338421A5060793722 @default.
• W4379338421 hasAuthorship W4379338421A5068824818 @default.
• W4379338421 hasAuthorship W4379338421A5075792907 @default.
• W4379338421 hasAuthorship W4379338421A5076085296 @default.
• W4379338421 hasAuthorship W4379338421A5077287358 @default.
• W4379338421 hasAuthorship W4379338421A5088647389 @default.
• W4379338421 hasAuthorship W4379338421A5090262803 @default.
• W4379338421 hasConcept C121608353 @default.
• W4379338421 hasConcept C126322002 @default.
• W4379338421 hasConcept C141071460 @default.
• W4379338421 hasConcept C143998085 @default.
• W4379338421 hasConcept C2776256026 @default.
• W4379338421 hasConcept C2778164965 @default.
• W4379338421 hasConcept C2779013556 @default.
• W4379338421 hasConcept C2781413609 @default.
• W4379338421 hasConcept C71924100 @default.
• W4379338421 hasConcept C90924648 @default.
• W4379338421 hasConceptScore W4379338421C121608353 @default.
• W4379338421 hasConceptScore W4379338421C126322002 @default.
• W4379338421 hasConceptScore W4379338421C141071460 @default.
• W4379338421 hasConceptScore W4379338421C143998085 @default.
• W4379338421 hasConceptScore W4379338421C2776256026 @default.
• W4379338421 hasConceptScore W4379338421C2778164965 @default.
• W4379338421 hasConceptScore W4379338421C2779013556 @default.
• W4379338421 hasConceptScore W4379338421C2781413609 @default.
• W4379338421 hasConceptScore W4379338421C71924100 @default.
• W4379338421 hasConceptScore W4379338421C90924648 @default.
• W4379338421 hasFunder F4320307105 @default.
• W4379338421 hasIssue "16_suppl" @default.
• W4379338421 hasLocation W43793384211 @default.
• W4379338421 hasOpenAccess W4379338421 @default.
• W4379338421 hasPrimaryLocation W43793384211 @default.
• W4379338421 hasRelatedWork W1602357875 @default.
• W4379338421 hasRelatedWork W2442673159 @default.
• W4379338421 hasRelatedWork W2516942920 @default.
• W4379338421 hasRelatedWork W2743740828 @default.
• W4379338421 hasRelatedWork W2888534976 @default.
• W4379338421 hasRelatedWork W3011176692 @default.
• W4379338421 hasRelatedWork W3139713181 @default.
• W4379338421 hasRelatedWork W3211406726 @default.
• W4379338421 hasRelatedWork W4221050677 @default.
• W4379338421 hasRelatedWork W4312517639 @default.
• W4379338421 hasVolume "41" @default.
• W4379338421 isParatext "false" @default.
• W4379338421 isRetracted "false" @default.
• W4379338421 workType "article" @default.